Những phát triển gần đây nhằm thu hẹp khoảng cách trong quản lý loãng xương

Kanis JA, Oden A, Johnell O et al (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417–427 Kanis JA, Borgstrom F, De Laet C, Johansson H et al (2005) Assessment of fracture risk. Osteoporos Int 16:581–589 World Health Organisation Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843. Geneva: WHO; 1994. https://apps.who.int/iris/bitstream/handle/10665/39142/WHO_TRS_843.pdf?sequence=1. Accessed 14 Dec 2020 Kanis J, McCloskey EV, Johansson H et al (2008) A reference standard for the description of osteoporosis. Bone 42:467–475 Kanis JA, Harvey NC, Johansson H et al (2020) A decade of FRAX: how has it changed the management of osteoporosis? Aging Clin Exp Res. 32(2):187–196 Siris ES, Brenneman SK, Miller PD, Barrett-Connor E, Chen Y, Sherwood LM, Abbott TA (2004) Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50-64 and 65 and older: results from the National Osteoporosis Risk Assessment (NORA). J Bone Miner Res 19:1215–1220 Rubin KH, Rothmann MJ, Holmberg T (2018) Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study. Osteoporos Int 29:567–578 Kanis JA, Seeman E, Johnell O et al (2005) The perspective of the International Osteoporosis Foundation on the Official Positions of the International Society for Clinical Densitometry. Osteoporos Int 16:456–459 Kanis JA, Johansson H, Oden A et al (2010) A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone 47:729–735 Kanis JA, Johansson H, Odén A et al (2011) A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX ®. Osteoporos Int 22:2347–2355 (with erratum Osteoporos Int. 22: 2357-2358) Harvey NC, Kanis JA, Odén A et al (2015) FRAX and the effect of teriparatide on vertebral and non-vertebral fracture. Osteoporos Int 26:2677–2684 Harvey NC, Kanis JA, Odén A et al (2015) Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX. Osteoporos Int 26:2347–2353 Kanis JA, Harvey NC, Johansson H et al (2017) FRAX update. J Clin Densitom 20:360–367 Kanis JA, Johnell O, Oden A et al (2000) Risk of hip fracture according to World Health Organization criteria for osteoporosis and osteopenia. Bone 27:585–590 Grigorie D, Sucaliuc A, Johansson H et al (2013) Incidence of hip fracture in Romania and the development of a Romanian FRAX model. Calcif Tissue Int 92:429–436 Kanis JA, Harvey NC, Cyrus Cooper C et al (2016) A systematic review of intervention thresholds based on FRAX. A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos 11:25 Kanis JA, McCloskey EV, Harvey NC et al (2015) Intervention thresholds and the diagnosis of osteoporosis. J Bone Miner Res 30:1747–1753 Johansson H, Azizieh F, Harvey NC et al (2017) FRAX- vs. T-score-based intervention thresholds for osteoporosis. Osteoporos Int 28:3099–3105 Kanis JA, Harvey NC, Johansson H et al (2017) Overview of fracture prediction tools. J Clin Densitom 20:360–367 Nguyen ND, Frost SA, Center JR et al (2008) Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int 19:1431–1444 Hippisley-Cox J, Coupland C (2012) Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. BMJ. 344:e3427 Kanis JA, Cooper C, Rizzoli R, Reginster J-Y, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF) (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30:3–44 Kanis JA, on behalf of the World Health Organization Scientific Group (2008) Assessment of osteoporosis at the primary healthcare level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK Available at: https://www.sheffield.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf. Accessed 19 Sept 2020 Johnell O, Oden A, Caulin F, Kanis JA (2001) Acute and long-term increase in fracture risk after hospitalization for vertebral fracture. Osteoporos Int 12:207–214 Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Pettersen C, De Laet C, Jonsson B (2004) Fracture risk following an osteoporotic fracture. Osteoporos Int 15:175–179 Nymark T, Lauritsen JM, Ovesen O, Röck ND, Jeune B (2006) Short time-frame from first to second hip fracture in the Funen County Hip Fracture Study. Osteoporos Int 17:1353–1357 Giangregorio LM, Leslie WD (2010) Manitoba bone density program. Time since prior fracture is a risk modifier for 10-year osteoporotic fractures. J Bone Miner Res 25:1400–1405 van Geel TACM, van Helden S, Geusens PP, Winkens B, Dinant GJ (2009) Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis 68:99–102 Johansson H, Siggeirsdóttir K, Harvey NC, Odén A, Gudnason V, McCloskey E, Sigurdsson G, Kanis JA (2017) Imminent risk of fracture after fracture. Osteoporos Int 28:775–780 Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, Möricke R, López-Romero P (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double dummy, randomised controlled trial. Lancet 391(10117):230–240 Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417–1427 Barrionuevo P, Kapoor E, Asi N, Alahdab F, Mohammed K, Benkhadra K, Almasri J, Farah W, Sarigianni M, Muthusamy K, Al Nofal A, Haydour Q, Wang Z, Murad MH (2019) Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. J Clin Endocrinol Metab 104:1623–1630 Lou S, Lv H, Yin P, Li Z, Tang P, Wang Y (2019) Combination therapy with parathyroid hormone analogs and antiresorptive agents for osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Osteoporos Int 30:59–70 Díez-Pérez A, Marin F, Eriksen EF, Kendler DL, Krege JH, Delgado-Rodríguez M (2019) Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: a systematic review and meta-analysis. Bone 120:1–8 Russow G, Jahn D, Appelt J, Märdian S, Tsitsilonis S, Keller J (2019) Anabolic therapies in osteoporosis and bone regeneration. Int J Mol Sci 20(1):83–100 Khosla S, Hofbauer LC (2017) Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol 5:898–907 Kanis JA, Harvey NC, McCloskey E et al (2020) Algorithm for the management of patients at low/middle/high risk of osteoporotic fracture: a global perspective. Osteoporos Int 31:1–12 Cosman F, Nieves JW, Dempster DW (2017) Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J Bone Miner Res 32:198–202 Kendler DL, Marin F, Zerbini CAF et al (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391:230–240 (Erratum Lancet 2018; 392: 2352) Compston J, Cooper A, Cooper C et al (2017) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 12:43 National Institute for Health and Care Excellence (NICE) (2017) Bisphosphonates for treating osteoporosis. Technology appraisal guidance, vol 464. National Institute for Health and Care Excellence, London https://www.nice.org.uk/guidance/ta464 (accessed on 20 Sept 2020) Kanis JA, Rizzoli R, Cooper C et al (2014) Challenges for the development of bone forming agents in Europe. Calcif Tissue Int 94:469–473 Leder BZ, Tsai JN, Neer RM et al (2016) Response to therapy with teriparatide, denosumab, or both in postmenopausal women in the DATA (Denosumab and Teriparatide Administration) study randomized controlled trial. J Clin Densitom 19:346–351 Bone HG, Cosman F, Miller PD et al (2018) ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab 103:2949–2957 Royal College of Physicians (1999) Osteoporosis: clinical guidelines for the prevention and treatment. RCP, London https://shop.rcplondon.ac.uk/products/osteoporosis-clinical-guidelines-for-prevention-and-treatment?variant=6634657349 (Accessed on 20 Sept 2020) Kanis JA, Delmas P, Burckhardt P et al (1997) Guidelines for diagnosis and management of osteoporosis. Osteoporos Int 7:390–406 Johansson H, Oden A, Johnell O et al (2004) Optimisation of BMD measurements to identify high risk groups for treatment—a test analysis. J Bone Miner Res 19:906–913 Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D (2019) pharmacological management of osteoporosis in postmenopausal women: an endocrine society* Clinical Practice Guideline. J Clin Endocrinol Metab. 104(5):1595–1622 Lewiecki EM, Dinavahi RV, Lazaretti-Castro M et al (2019) One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study. J Bone Miner Res. 34(3):419–428 Compston JE, McClung M, Leslie W (2019) Osteoporosis. Lancet 393(10169):364–376 Cosman F (2014) Anabolic and antiresorptive therapy for osteoporosis: combination and sequential approaches. Curr Osteoporos Rep. 12(4):385–395 Tsai JN, Uihlein AV, Lee H et al (2013) Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet. 382(9886):50–56 Leder BZ, Tsai JN, Uihlein AV et al (2014) Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab. 99(5):1694–1700 Cosman F, Eriksen EF, Recknor C et al (2011) Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res. 3:503–511 Tsai JN, Lee H, David NL et al (2019) Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial. Lancet Diabetes Endocrinol. 7(10):767–775 Ramchand SK, David NL, Leder BZ et al (2020) Bone mineral density response with denosumab in combination with standard or high dose teriparatide: the DATA-HD RCT. J Clin Endocrinol Metab 105(3):890–897 Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R (2020) Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update. J Clin Endocrinol Metab 1:1595–1622